Prelude Therapeutics annual shares outstanding
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Shares Outstanding History (PRLD)
Prelude Therapeutics reported 63.0M shares outstanding at the end of fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 63.0M | 7.8M | +14.23% |
| 2024 | 2024-12-31 | 55.2M | 234,040 | +0.43% |
| 2023 | 2023-12-31 | 54.9M | 7.0M | +14.63% |
| 2022 | 2022-12-31 | 47.9M | 281,128 | +0.59% |
| 2021 | 2021-12-31 | 47.6M | 1.0M | +2.25% |
| 2020 | 2020-12-31 | 46.6M | — | — |
Prelude Therapeutics quarterly shares outstanding
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 79.8M | 23.2M | +40.99% |
| Q1 2026 | 2026-03-31 | 79.6M | 23.2M | +41.06% |
| Q4 2025 | 2025-12-31 | 63.0M | 7.8M | +14.23% |
| Q3 2025 | 2025-09-30 | 62.9M | 7.8M | +14.23% |
| Q2 2025 | 2025-06-30 | 56.6M | 1.6M | +2.86% |
| Q1 2025 | 2025-03-31 | 56.5M | 1.5M | +2.79% |
| Q4 2024 | 2024-12-31 | 55.2M | 234,040 | +0.43% |
| Q3 2024 | 2024-09-30 | 55.0M | 209,188 | +0.38% |
| Q2 2024 | 2024-06-30 | 55.0M | 215,755 | +0.39% |
| Q1 2024 | 2024-03-31 | 54.9M | 7.0M | +14.54% |
| Q4 2023 | 2023-12-31 | 54.9M | 7.0M | +14.63% |
| Q3 2023 | 2023-09-30 | 54.8M | 7.0M | +14.56% |
| Q2 2023 | 2023-06-30 | 54.8M | 7.0M | +14.58% |
| Q1 2023 | 2023-03-31 | 48.0M | 259,366 | +0.54% |
| Q4 2022 | 2022-12-31 | 47.9M | 281,128 | +0.59% |
| Q3 2022 | 2022-09-30 | 47.9M | 644,461 | +1.36% |
| Q2 2022 | 2022-06-30 | 47.8M | 739,776 | +1.57% |
| Q1 2022 | 2022-03-31 | 47.7M | 737,441 | +1.57% |
| Q4 2021 | 2021-12-31 | 47.6M | 1.0M | +2.25% |
| Q3 2021 | 2021-09-30 | 47.2M | 3.5M | +8.04% |
| Q2 2021 | 2021-06-30 | 47.1M | — | — |
| Q1 2021 | 2021-03-31 | 47.0M | — | — |
| Q4 2020 | 2020-12-31 | 46.6M | 0 | 0.00% |
| Q3 2020 | 2020-09-30 | 43.7M | — | — |
| Q4 2019 | 2019-12-31 | 46.6M | — | — |
Prelude Therapeutics shares outstanding trends
Over the last five fiscal years, Prelude Therapeutics's shares outstanding moved from 46.6M to 63.0M, a change of 16.4M. The latest reported quarter, Q2 2026, shows 79.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...